Enhabit (EHAB) Q3 2024 Earnings Call Transcript

Q3 consolidated net revenue was $253.6M (-1.8% YoY) while consolidated adjusted EBITDA rose to $24.5M (+5.6% YoY). Home health revenue fell $9.9M (-4.7%) driven by recertification declines despite non‑Medicare admissions +20.1% and payor innovation covering 45% of non‑Medicare visits; hospice revenue grew $5.2M (+11%) with average daily census +6.9% and an ~4% hospice reimbursement increase (~$8M annualized). Liquidity and cash flow improved (YTD free cash flow ~$59M, conversion 79%; available liquidity ~$94M; leverage 4.8x) and 2024 guidance was updated to net service revenue $1,031M–$1,046M, adjusted EBITDA $98M–$102M and free cash flow $47M–$55M, while management flags CMS reimbursement pressure, hurricane-related Q4 impact (~$2M), branch consolidations (8–10) and a CFO transition.

Analysis

Enhabit’s playbook — shift volume into higher-paying, value-based contracts while pruning underperforming capacity — creates a two-speed outcome: margin improvement from structural payor mix shifts and cost outs, but permanently lower organic capacity in markets that are consolidated. The second-order risk is market share erosion in localized referral ecosystems: closing branches hands competitors (or nimble independents) referral relationships that can be hard to win back, so realized margin gains could come at the expense of future revenue optionality.

Operational levers (outsourcing coding, care-management reorg) lower fixed cost but concentrate execution risk into vendors and centralized processes; a coding error rate increase of even low-single-digit percentage points could wipe out a meaningful share of the quarterly EBITDA improvement management projects. Near-term catalysts that will reprice the stock are binary and time-boxed: the payer negotiation outcome, the Q4 call quantifying 2025 savings, and any legislative relief on Medicare reimbursement — each sits on a 1–6 month horizon and will materially re-rate risk premia.

For counterparties and competitors, national payers that can procure scaled, predictable value-based capacity become preferred partners — meaning operators that win “payor innovation” slots could see durable premium valuation multiples while those stuck with legacy Medicare Advantage shrinking recertifications will trade like remediation turnarounds. Hurricane-driven concentration risk also implies insurance and contingency-capacity exposures that underwriters and acquirers will price into future M&A — making opportunistic acquisitions of divested branches plausible in 2025 if execution proves crisp.

Key Decisions for Investors

• Long EHAB equity (ticker: EHAB) sized 0.5–1.0% NAV, entry window: next 2–8 weeks as hurricane noise decays. Use a 12-month horizon to capture realized 2025 cost saves and hospice rate carry; target 30–40% upside if CMS/labor and payor deals materialize; hard stop 25% below entry (or hedge with puts).
• Long-call overwriting alternative: buy 12–15 month LEAP calls on EHAB (calculated notional = 0.5% NAV) to cap downside while retaining upside into the Jan–Mar 2025 earnings cadence; roll if United negotiation remains unresolved by Jan 31, 2025.
• Pair trade to isolate operational vs macro execution: long EHAB (0.5% NAV) / short AMED (Amedisys, ticker: AMED) equal notional, time horizon 6–12 months. Rationale: capture relative outperformance if Enhabit’s payor-innovation and hospice mix re-rate; risk: AMED outperforms on scale-driven Medicare stabilization — monitor MA exposure weekly.
• Event hedge: buy EHAB one-quarter OTM puts expiring just after the Q4 earnings call (size 25–50% of equity exposure) to protect against downside from adverse United negotiation or coding-outsourcing hiccups. This compresses downside tail risk at modest cost while preserving upside optionality.